Clinical manifestations in patients with PI*MM\text{Malton} genotypes. A matter still unsolved in alpha-1 antitrypsin deficiency

Marina Aiello\(^1\), Alberto Fantin\(^1\), Chiara Longo\(^1\), Ilaria Ferrarotti\(^2\), Giuseppina Bertorelli\(^1\) & Alfredo Chetta\(^1\)

\(^1\)Department of Medicine and Surgery, Respiratory Disease and Lung Function Unit, University of Parma, Italy.
\(^2\)Center for the Diagnosis of Inherited Alpha-1-antitrypsin Deficiency, Department of Internal Medicine and Therapeutics, Pneumology Unit, University of Pavia, Italy.

Keywords
Alpha-1 antitrypsin deficiency, genotype, lung and liver function.

Abstract
We report the genetic variants associated with alpha-1 antitrypsin deficiency (AATD) in 117 patients admitted to our outpatient clinic and characterized by a serum concentration of AAT lower than 113 mg/dL. We focused on the M-like heterozygous variant of the \textit{SERPINA1} gene called PI\*MM\text{Malton}, and describe three patients with this variant. While the role of homozygous AATD in liver and pulmonary disease is well established, the association between heterozygous AATD and chronic liver and pulmonary disease is still under investigation. The PI\*MM\text{Malton} genotype was found in 5.8\% of patients with a pathological genotype of AATD and in 14.3\% of the subjects when considering only those with intermediate AATD. There were no liver or renal abnormalities in patients with the PI\*MM\text{Malton} genotype. The PI\*MM\text{Malton} patients included here showed a normal liver function, and none had renal function abnormalities or abdominal aortic aneurysm. Only a prevalence of lung disease was detected.

Introduction
Alpha-1 antitrypsin deficiency (AATD) is an autosomal co-dominant genetic disorder characterized by a decreased serum concentration of alpha-1 antitrypsin (AAT). A deficiency of this protein predisposes to the onset of pulmonary emphysema, bronchial asthma, bronchiectasis, hepatopathy unrelated to other conditions, panniculitis, arterial aneurysms, and vasculitis, such as granulomatosis with polyangiitis [1]. AAT functions mainly as a protease inhibitor. A decreased plasma concentration of AAT leads to an imbalance between its protective activity and the proteolytic activity of neutrophil elastase.

AAT, a small glycoprotein encoded by a gene located on chromosome 14, belongs to the serine protease family (Serpin) and is synthesized and released mainly by hepatocytes. The Z variant is the most common, clinically significant, deficient variant, characterized by the replacement of amino acid Glu342 to Lys342. Among other rare pathological variants, the so called “M-like” variants (e.g. M\text{Malton}, M\text{Wurzburg}, M\text{Procida}, etc.) play an interesting role. These mutations produce an isoelectrophoretic pattern similar to the normal M variants; consequently, a phenotypic analysis can misdiagnose these variants as normal and only the gene sequencing allows their univocal identification [2].

The aim of this study was to analyse the genetic variants associated with AATD in 117 patients admitted to our outpatient clinic and characterized by a serum concentration of AAT lower than 113 mg/dL. Blood samples from these patients were taken in ethylenediaminetetraacetic acid (EDTA) or by using the AlphaKit™ (Whatman, GE Healthcare; Maidstone, UK) test [3]. DNA was extracted and amplified through real-time polymerase chain reaction. The amplification products were then analysed by electrophoresis on 2\% agarose gel in TBE buffer (Tris-Borate-EDTA) and sequenced through the Sanger enzymatic method. In our study, we focused in particular on the M-like heterozygous variants of the \textit{SERPINA1} gene.
called PI*MMMalton (p.F75del, c.227-229del rs775982338). The study was approved by our local Ethics Committee. All patients signed an informed consent form authorizing the use of their data for this study.

Fifty-two out of the 117 patients undergoing genetic investigation showed a pathological genotype, while 65 patients had a PI*MM genotype. In more detail, the pathological genotypes we found were: PI*MS (24 patients), PI*MZ (16 patients), PI*SZ (three patients), PI*MMMalton (three patients), PI*SS (two patients), PI*MMWurzburg (two patients), PI*ZZ (one patient), and PI*VZ (one patient). Twenty-seven out of the 52 patients with a pathological genotype were admitted to our outpatient clinic because of respiratory problems, while the remaining 25 subjects were relatives of the index cases (52% and 48% of the total, respectively).

The patients with the PI*MMMalton variant corresponded to 6% of all the patients analysed. A discussion of these three clinical cases will follow below.

Case Series

Case 1

A 43-year-old male subject, Italian Caucasian, affected by asthma and atopy, with prick tests positive since the childhood for dog and cat dander and grass pollen, treated with inhaled corticosteroids, long-acting β2-agonists (ICS/LABAs) and long-acting muscarinic antagonists (LAMAs). The patient referred to our outpatient clinic for recurrent bronchitis and exertional dyspnoea. He was a former smoker (about 10 cigarettes a day for 20 years, 10 pack/years) at the time of the visit and a manual worker with no previous exposure to any toxic or irritating agent.

Upon auscultation, he presented a slightly reduced vesicular murmur, with wheezing during forced expiration; oxygen saturation (SatO2) was 96% breathing room air and the heart rate was 71 bpm. Arterial blood gas measurement in breathing room air produced the following results: pH 7.46, pCO2 37 mmHg, pO2 91 mmHg, HCO3 27 mmoL/L, and sO2 97%.

AAT serum concentration was 64 mg/dL, with a PI*MMMalton genotype. Complete abdomen ultrasound exam did not identify hepatic or aneurysmal disease. Total and fractioned bilirubin, creatine phosphokinase (CPK), gamma-glutamyl transferase (gamma GT), cholinesterase, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) blood tests were in the normal range, as well as urea and creatinine; anti-neutrophil cytoplasmic antibodies (C-ANCA) and anti-myeloperoxidase antibodies (anti-MPO) were negative, while a marked increase in total IgE was detected (1260 IU/mL). Autoantibodies and eosinophils were also in the normal range.

Lung function tests showed an extremely severe obstructive ventilatory defect. The bronchial reversibility test was positive (Fig. 1; Table 1). The chest high resolution computed tomography (HRCT) excluded pulmonary emphysema, bronchiectasis and fibrosis. The six-minute walking test (6MWT), performed without oxygen supplementation, did not register any clinically significant desaturation but a slight reduction in the distance walked (440 m measured/546 m predicted). Echocardiographic parameters were in the normal range.

Case 2

A 62-year-old male subject, Italian Caucasian, in good health conditions. The diagnosis of AATD was made following genotype analysis performed on the son of the subject (the patient in Case 1, with a PI*MMMalton genotype). The patient had an AAT serum concentration of 69 mg/dL, with a PI*M3Malton genotype. He was a former smoker (about four cigarettes a day for 5 years, 1 pack/years), and worked as a sandblaster craftsman, reporting powder working exposure.

The patient did not take any drug, and did not complain of any respiratory symptoms. The 6MWT, performed without oxygen supplementation, did not register a clinically significant desaturation and the distance walked was normal (424 m measured/530 m predicted). SatO2 was 100% breathing room air and the heart rate was 66 bpm. Upon thoracic auscultation, the vesicular murmur was preserved, with no pathological sound. Lung function tests were in the normal range (Table 2). Blood count, liver function tests and renal function were in the standard reference range, while the total IgE concentration was
429 IU/mL. Chest X-ray showed no abnormality. Liver and abdominal ultrasound exams were negative for liver or aneurysmal disease. Prick tests were positive for dust mites, whereas bronchial hyperactivity assessed through the methacholine (MCh) test was negative.

Case 3

A 50-year-old male subject of Tunisian origin, followed by our outpatient chronic obstructive pulmonary disease (COPD) clinic, a former smoker (about 10 cigarettes a day for 30 years, 15 pack/years) treated with a LAMA-based inhalation therapy, and with previous monolateral spontaneous pneumothorax, treated with thoracic drainage. He worked as a driver. The patient presented digital hippocratism and, upon chest auscultation, the vesicular murmur was greatly reduced.

Arterial blood gas analysis showed values in the normal range considering the subject’s age: pH 7.35, pCO₂ 42.9 mmHg, pO₂ 89.5 mmHg, HCO₃ 22.6 mmol/L, and sO₂ 97%. The 6MWT, performed without oxygen supplementation, did not register any clinically significant desaturation but a slight reduction in the distance walked (411 m measured/512 m predicted). Electrocardiogram (ECG) parameters were within the normal limits. The chest HRCT showed a severe diffuse centrolobular and paraseptal emphysema (Fig. 2).

Pulmonary function tests revealed a mild airway obstruction, with a negative bronchial reversibility test (Fig. 3; Table 1).

Since the AAT serum concentration was lower than normal (87 mg/dL), the patient underwent a genetic investigation with verification of the PI*MMMalton genotype. Blood chemistry tests (total and fractionated bilirubin, CPK, gamma GT, cholinesterase, AST, ALT and renal function indices) were in the normal range. Liver and abdominal ultrasound exams were negative for liver or aneurysmal disease.

Discussion

Our study revealed the frequency of rare genetic variants in a wide cohort of subjects affected by AATD, where the patients with PI*MMMalton and PI*MMWurzburg genotypes were respectively 5.8% and 3.8% of all patients with a
pathological genotype. However, when only the subjects with intermediate AATD were considered, the prevalence of these two genotypes increased to 14.3% and 9.5%, respectively. These frequencies are close to the frequency of the PI*MMMalton genotype among patients with intermediate AATD included in the Italian National Registry (9.3%) [4]. The Alpha-1 Foundation Research Registry Network [5] includes subjects with intermediate AATD showing a prevalence of 5.3% of rare AAT variants, lower than in the Italian National Registry.

Regarding the M_Malton variant, Cox et al. [6] found the M_Malton genotype in a family without hepatic or pulmonary disease. However, the study was limited by the fact that all the patients were under 30 years of age, and therefore could not have had the time to develop the aforementioned pathologies.

Sproule et al. found a severe emphysema in four patients with PI*type M_MaltonZ, however they did not find any difference in lung function tests between heterozygotes with PI type MM_Malton and subjects with PI*MM. The authors showed a synergistic effect of cigarette smoke and intermediate AATD, in fact the PI*MM_Malton genotypes were associated with a significantly impaired lung function in smokers only [7].

Other authors, while confirming the association between PI*M_MaltonZ and a high risk of developing emphysema, in contrast to the study by Sproules et al., did not find any evidence suggesting that smokers with PI*MM_Malton genotypes and intermediate AAT serum concentration have a greater risk of developing emphysema than smokers with normal AAT serum concentration [8].

Reid and co-workers presented a patient homozygous for the variant PI*M_Malton and affected by severe AATD who developed emphysema, cirrhosis and hepatocellular carcinoma [9].

Joly et al. evaluated four patients with M_Malton type M-like genotype, and in particular a patient with PI*MM_Malton/MM_Malton genotype, two PI*MM_Malton/Z patients and a PI*M/M_Malton patient. In the two patients with double heterozygosis, the clinical picture was represented by COPD, without hepatic alterations; the homozygous patient, on the other hand, was affected by hepatic cirrhosis, with small bronchiectasis but without emphysema; the last case, with a simple heterozygous genotype, suffered from end-stage renal failure, but without liver or lung abnormalities [10].

Figueira et al. have recently shown that patients with intermediate AATD and PI*MM_Malton genotype have a high incidence of lung disease without relevant hepatic manifestations [11].

Consistently with the Figueira et al. findings, the patients with a PI*MM_Malton genotype did not show any liver or renal abnormalities, but only pulmonary pathologies, that is atopy and asthma in Case 1, atopy in Case 2, emphysema and pneumothorax in Case 3. In addition, two out of the three patients had a moderate-to-severe lung function impairment.

In Case 2, the PI*MM_Malton genetic defect was associated with good healthy conditions and a normal pulmonary, hepatic, and renal clinical picture. This aspect highlights the fact that, although the patients described in Cases 1 and 2 are relatives, have the same genetic defect and the same exposure to cigarette smoking, the AATD
can be clinically expressed in completely different ways. This observation underscores how the presence of other non-environmental factors, such as genetic modifiers not yet identified, can play an important role in the evolution of the clinical manifestations in these patients [12].

In addition to normal liver function, none of the three patients had abdominal aortic aneurysms. The three patients included in our study were ex-smokers. It has been reported in literature that smoking, in addition to potentiating lung injury, reduces the antiprotease activity of the AAT molecule by approximately 2000 times [13], making it an important, avoidable factor for the development of emphysema. As for smoking, it is interesting to note that, among patients with pulmonary disease, more than 50% of subjects are ex-smokers. Smoking cessation is therefore a very important intervention to be implemented [14].

In conclusion, our data showed that the rare M-like variants with a PI*MMMalton genotype represent a high percentage among patients with intermediate AATD, that appear to be mostly affected at respiratory level, with a strong association to cigarette smoke exposure, without an evident hepatic involvement.

Disclosure statements
Appropriate written informed consent was obtained for publication of this case series and accompanying images.

References
1. Ranes J, and Stoller JK. 2012. A review of alpha1-antitrypsin deficiency. Am. J. Respir. Crit. Care Med. 185(3):246–259.
2. Miravitlles M, Dirksen A, Ferrarotti I, et al. 2017. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in alpha1-antitrypsin deficiency. Eur. Respir. J. 50(5):1700610.
3. Gorrini M, Ferrarotti I, Lupi A, et al. 2006. Validation of a rapid, simple method to measure alpha1-antitrypsin in human dried blood spots. Clin. Chem. 52(5):899–901.
4. Ferrarotti I, Baccheschi J, Zorzetto M, et al. 2005. Prevalence and phenotype of subjects carrying rare variants in the Italian registry for alpha1-antitrypsin deficiency. J. Med. Genet. 42(3):282–287.
5. Stoller JK, Brantly M, Fleming LE, et al. 2000. Formation and current results of a patient-organized registry for alpha (1)-antitrypsin deficiency. Chest 118(3):843–848.
6. Cox DW. 1976. A new deficiency allele of alpha1-antitrypsin: Pi MMmalton. Peeters H, ed. Protides of the Biological Fluids, Vol. 23:375–378. Oxford, England: Pergamon.
7. Sproule BJ, Cox DW, Hsu K, et al. 1983. Pulmonary function associated with the Mmalton deficient variant of alpha 1-antitrypsin. Am. Rev. Respir. Dis. 127(2):237–240.
8. Allen MB, Ward AM, and Perks WH. 1986. Alpha 1 antitrypsin deficiency due to MMaltonZ phenotype: case report and family study. Thorax 41(7):568–570.
9. Reid CI, Wiener GJ, Cox DW, et al. 1987. Diffuse hepatocellular dysplasia and carcinoma associated with the Mmalton variant of alpha 1-antitrypsin. Gastroenterology 93(1):181–187.
10. Joly P, Guillaud O, Hervieu V, et al. 2015. Clinical heterogeneity and potential high pathogenicity of the Mmalton alpha 1 antitrypsin allele at the homozygous, compound heterozygous and heterozygous states. Orphanet J. Rare Dis. 10:130.
11. Figueira JM, Bugallo FM, Díaz Pérez D, et al. 2017. Clinical manifestations of the Mmalton alpha-1 antitrypsin deficiency variant. Pulmonology pii:S2173-5115(17)30168-9.
12. Wood AM, Needham M, Simmonds MJ, et al. 2008. Phenotypic differences in alpha 1 antitrypsin-deficient sibling pairs may relate to genetic variation. COPD 5(6):353–359.
13. Ogushi F, Fells GA, Hubbard RC, et al. 1987. Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin. J. Clin. Invest. 80:1366–1374.
14. Janoff A et al. 1985. Elastases and emphysema. Current assessment of the protease-antiprotease hypothesis. Am. Rev. Respir. Dis. 132(2):417–433.